The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | Treating high risk CLL with BTK inhibitors
Deborah M. Stephens, DO, of Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, discusses treatments for young and fit patients who are at high risk and are newly diagnosed with chronic lymphocytic leukemia (CLL). The use of Bruton tyrosine kinase (BTK) inhibitors are preferentially used for this patient population whilst novel agents in combination with BTK inhibitors are currently being explored. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
